See more : Gowra Leasing and Finance Limited (GOWRALE.BO) Income Statement Analysis – Financial Results
Complete financial analysis of Jubilant Pharmova Limited (JUBLPHARMA.NS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Jubilant Pharmova Limited, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Sun Max Tech Limited (6591.TW) Income Statement Analysis – Financial Results
- Valero Energy Corporation (VLO) Income Statement Analysis – Financial Results
- Selan Exploration Technology Limited (SELAN.NS) Income Statement Analysis – Financial Results
- Resideo Technologies, Inc. (REZI) Income Statement Analysis – Financial Results
- Banco Inter S.A. (BIDI11.SA) Income Statement Analysis – Financial Results
Jubilant Pharmova Limited (JUBLPHARMA.NS)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.jubilantpharmova.com
About Jubilant Pharmova Limited
Jubilant Pharmova Limited operates as an integrated pharmaceutical company worldwide. It operates through three segments: Pharmaceuticals; Contract Research & Development Services; and Proprietary Novel Drugs. The Pharmaceuticals segment engages in the manufacturing and supply of allergy therapy products, contract manufacturing of sterile injectables and non-sterile products, active pharmaceutical ingredients, and solid dosage formulations, as well as sale of radiopharmaceuticals through a network of 48 radio pharmacies in the United States. The Contract Research & Development Services segment provides collaborative research services to pharmaceutical innovators. The Proprietary Novel Drugs segment develops therapies in the areas of oncology and auto-immune disorders. The company was formerly known as Jubilant Life Sciences Limited and changed its name to Jubilant Pharmova Limited in February 2021. The company was incorporated in 1978 and is headquartered in Noida, India.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 66.45B | 62.19B | 60.59B | 59.64B | 89.77B | 89.97B | 74.25B | 57.65B | 57.00B | 57.76B | 57.22B | 51.43B | 43.03B | 34.33B | 37.81B | 35.18B | 24.89B | 18.10B | 15.05B | 11.70B | 8.59B |
| Cost of Revenue | 47.39B | 18.78B | 17.87B | 17.53B | 34.54B | 38.21B | 31.44B | 22.52B | 23.71B | 29.18B | 26.87B | 20.50B | 22.32B | 13.70B | 30.46B | 16.40B | 11.69B | 9.69B | 12.88B | 6.61B | 4.38B |
| Gross Profit | 19.06B | 43.41B | 42.72B | 42.10B | 55.22B | 51.76B | 42.81B | 35.13B | 33.30B | 28.58B | 30.35B | 30.93B | 20.71B | 20.64B | 7.35B | 18.78B | 13.20B | 8.41B | 2.17B | 5.09B | 4.21B |
| Gross Profit Ratio | 28.69% | 69.80% | 70.51% | 70.60% | 61.52% | 57.53% | 57.66% | 60.94% | 58.41% | 49.47% | 53.04% | 60.14% | 48.14% | 60.11% | 19.45% | 53.40% | 53.02% | 46.46% | 14.42% | 43.50% | 49.03% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 185.05M | 202.20M | 182.05M | 161.64M | 131.16M | 71.60M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 2.26B | 2.23B | 2.46B | 2.32B | 2.46B | 2.68B | 1.46B | 1.02B | 971.38M | 1.24B | 1.06B | 7.64B | 1.92B | 3.67B | 0.00 | 4.22B | 3.34B | 2.70B | 0.00 | 1.86B | 1.46B |
| Selling & Marketing | 2.14B | 1.53B | 1.56B | 1.49B | 2.32B | 2.18B | 1.96B | 1.33B | 1.20B | 1.28B | 1.61B | 1.23B | 1.12B | 1.62B | 0.00 | 1.18B | 948.66M | 785.09M | 0.00 | 467.81M | 319.33M |
| SG&A | 14.45B | 3.76B | 4.02B | 3.81B | 4.78B | 4.85B | 3.42B | 2.35B | 2.17B | 2.52B | 2.67B | 8.87B | 3.04B | 5.30B | 0.00 | 5.40B | 4.29B | 3.49B | 0.00 | 2.33B | 1.78B |
| Other Expenses | 0.00 | 383.30M | 86.90M | 67.18M | 115.14M | 125.48M | 226.88M | 159.32M | 109.04M | 134.08M | 113.58M | 175.45M | -39.53M | 11.60B | 670.48M | 7.89B | 4.00B | 2.57B | 316.41M | 1.32B | 1.12B |
| Operating Expenses | 14.45B | 41.19B | 34.48B | 30.92B | 40.34B | 37.94B | 31.74B | 24.40B | 23.89B | 24.55B | 23.07B | 22.83B | 13.84B | 16.89B | 670.48M | 13.29B | 8.29B | 6.05B | 316.41M | 3.65B | 2.90B |
| Cost & Expenses | 61.82B | 59.97B | 52.35B | 48.45B | 74.89B | 76.15B | 63.17B | 46.92B | 47.60B | 53.74B | 49.94B | 43.33B | 36.16B | 30.59B | 31.13B | 29.68B | 19.98B | 15.74B | 13.20B | 10.26B | 7.28B |
| Interest Income | 261.00M | 98.28M | 24.51M | 80.97M | 215.27M | 109.68M | 51.30M | 87.79M | 27.39M | 62.40M | 52.20M | 113.05M | 161.95M | 0.00 | 50.54M | 0.00 | 267.03M | 0.00 | 55.30M | 0.00 | 0.00 |
| Interest Expense | 2.72B | 1.88B | 1.38B | 1.73B | 2.73B | 2.06B | 2.64B | 3.01B | 3.42B | 3.27B | 3.06B | 2.36B | 2.10B | 1.05B | 1.51B | 1.07B | 350.80M | 0.00 | 172.66M | 220.36M | 0.00 |
| Depreciation & Amortization | 3.82B | 5.54B | 3.82B | 3.49B | 3.40B | 3.71B | 3.24B | 2.88B | 3.46B | 2.88B | 2.81B | 2.54B | 2.61B | 1.93B | 1.25B | 1.63B | 1.63B | 622.86M | 536.86M | 381.40M | 326.18M |
| EBITDA | 8.09B | 7.58B | 11.68B | 13.93B | 15.52B | 14.93B | 14.67B | 13.66B | 12.39B | 6.96B | 10.30B | 8.36B | 5.61B | 5.39B | 7.93B | 5.67B | 5.94B | 4.05B | 2.39B | 2.26B | 1.64B |
| EBITDA Ratio | 12.17% | 13.29% | 19.04% | 25.51% | 22.09% | 19.73% | 20.65% | 23.18% | 22.18% | 11.81% | 17.63% | 20.62% | 21.95% | 15.69% | 20.97% | 20.10% | 25.75% | 16.27% | 15.88% | 15.52% | 18.91% |
| Operating Income | 5.19B | 3.75B | 8.40B | 11.44B | 12.39B | 13.82B | 11.07B | 10.73B | 9.41B | 4.02B | 7.28B | 8.10B | 6.87B | 3.74B | 6.68B | 5.50B | 4.91B | 2.35B | 1.85B | 1.44B | 1.31B |
| Operating Income Ratio | 7.81% | 6.03% | 13.86% | 19.19% | 13.80% | 15.36% | 14.92% | 18.62% | 16.50% | 6.97% | 12.72% | 15.75% | 15.97% | 10.91% | 17.68% | 15.63% | 19.71% | 13.00% | 12.32% | 12.33% | 15.25% |
| Total Other Income/Expenses | -3.48B | -3.47B | -1.85B | -2.39B | -1.95B | -4.78B | -2.70B | -3.36B | -4.00B | -3.62B | -5.21B | -4.63B | -5.54B | -1.34B | -1.51B | -1.07B | -343.98M | 599.89M | -104.96M | 198.40M | -343.93M |
| Income Before Tax | 1.71B | 277.80M | 6.30B | 8.71B | 12.11B | 9.04B | 8.59B | 7.38B | 5.84B | 403.24M | 2.07B | 3.41B | 1.14B | 2.41B | 5.18B | 2.97B | 4.56B | 2.95B | 1.68B | 1.64B | 966.28M |
| Income Before Tax Ratio | 2.57% | 0.45% | 10.40% | 14.61% | 13.49% | 10.05% | 11.57% | 12.79% | 10.25% | 0.70% | 3.62% | 6.63% | 2.65% | 7.01% | 13.70% | 8.43% | 18.33% | 16.32% | 11.17% | 14.02% | 11.25% |
| Income Tax Expense | 978.00M | 926.60M | 2.17B | 2.97B | 3.12B | 3.27B | 2.25B | 1.63B | 1.53B | 804.84M | 696.44M | 1.52B | 684.14M | 133.65M | 959.44M | -267.19M | -572.84M | -712.49M | 392.44M | -431.59M | -179.00M |
| Net Income | 771.00M | -609.80M | 4.14B | 8.36B | 8.98B | 5.74B | 6.43B | 5.76B | 4.31B | -577.64M | 1.09B | 1.53B | 145.61M | 2.30B | 4.21B | 2.83B | 4.00B | 2.28B | 1.30B | 1.19B | 782.37M |
| Net Income Ratio | 1.16% | -0.98% | 6.83% | 14.02% | 10.01% | 6.38% | 8.66% | 9.98% | 7.57% | -1.00% | 1.91% | 2.97% | 0.34% | 6.69% | 11.15% | 8.05% | 16.09% | 12.60% | 8.61% | 10.19% | 9.11% |
| EPS | 4.86 | -3.83 | 26.01 | 52.48 | 56.39 | 36.10 | 41.25 | 36.93 | 25.10 | -3.63 | 6.85 | 9.59 | 0.91 | 14.42 | 28.56 | 18.30 | 26.50 | 15.17 | 9.03 | 9.41 | 6.35 |
| EPS Diluted | 4.85 | -3.83 | 26.01 | 52.48 | 56.39 | 36.10 | 41.25 | 36.91 | 25.08 | -3.63 | 6.85 | 9.59 | 0.91 | 13.04 | 24.66 | 15.77 | 21.35 | 12.40 | 8.16 | 8.90 | 6.35 |
| Weighted Avg Shares Out | 158.51M | 159.15M | 159.17M | 159.27M | 159.28M | 159.13M | 159.13M | 159.13M | 159.13M | 159.13M | 159.28M | 159.28M | 159.28M | 159.13M | 159.13M | 159.13M | 159.13M | 159.13M | 159.13M | 159.13M | 159.13M |
| Weighted Avg Shares Out (Dil) | 158.86M | 159.15M | 159.17M | 159.27M | 159.28M | 159.13M | 159.13M | 159.13M | 159.13M | 159.28M | 159.28M | 159.28M | 159.28M | 159.13M | 159.13M | 159.13M | 159.13M | 159.13M | 159.13M | 159.13M | 159.13M |
Source: https://incomestatements.info
Category: Stock Reports